RDPC, randomized, double-blind, placebo-controlled
Glycine has been shown in animal studies to improve insulin sensitivity and reduce inflammation in metabolic syndrome models
GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone which means it is produced in your gut
It is an empowering approach, but it must never come at the expense of your health
The benefit was not observed in all-cause death (HR 0.99, 95% CI 0.841.15), hospitalization for heart failure (HR 1.04, 95% CI 0.891.22), cardiovascular death (HR 0.95, 95% CI 0.791.16), myocardial infarction (HR 0.88, 95% CI 0.711.08), stroke (HR 1.03, 95% CI 0.751.43) and death or hospitalization for HF (HR 1.07, 95% CI 0.781.46)
Meta-analyses including over 40,000 individuals demonstrate a decreased risk of composite renal outcomes (HR 0.79, 95% CI 0.720.87), confirming renal protection as a class effect independent of cardiovascular advantages (Mavrakanas et al